Milvexian for the Prevention of Venous Thromboembolism

New England Journal of Medicine
In this Phase II study of patients undergoing knee arthroplasty (n=1242), the oral factor XIa inhibitor milvexian was associated with venous thromboembolism in 7% to 25% depending on the dose used, as compared to 21% taking enoxaparin 40mg once daily.

Comparison of the HAS-BLED versus ORBIT Scores in Predicting Major Bleeding Among Asians Receiving the Direct-Acting Oral Anticoagulants

British Journal of Clinical Pharmacology
Thai retrospective study (n=961) found HAS-BLED and ORBIT scores showed a similar moderate predictive performance on bleeding using the C-statistic test, with no significant difference between scores (0.65 vs 0.64, p=0.62).

NHS England strikes new agreement to expand use of DOACs for atrial fibrillation

NHS England
NHS England are intending to scale up the use of DOACs with as many as 610,000 more patients expected to benefit over the next three years. A procurement deal on DOACs has been reached to help expand access by making treatment more affordable.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services